STOCK TITAN

NanoViricides Inc - NNVC STOCK NEWS

Welcome to our dedicated news page for NanoViricides (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on NanoViricides.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NanoViricides's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NanoViricides's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.69%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.64%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.67%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.63%
Tags
covid-19
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.8%
Tags
covid-19
NanoViricides Inc

NYSE:NNVC

NNVC Rankings

NNVC Stock Data

14.72M
11.24M
4.62%
10.3%
0.84%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Shelton

About NNVC

nanoviricides, inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. its products pipeline includes herpecide dermal topical and eye drops for the treatment of shingles, phn, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and herpecide intraocular injection for viral acute retinal necrosis. the company also develops flucide broad-spectrum anti-influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; nanoviricide eye drops for viral diseases of the external eye; denguecide for treatment of all types of dengue viruses; and hivcide that is an escape-resistant anti-hiv nanoviricide. in addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and herpecide program expansion drug projects for different herpes viruses for different indications. nanovir